Digital Media briefs

Share this article:
Novo Nordisk launched NovoDose, an iPhone app that serves as a mobile insulin dosing guide for physicians, who can look up dosing guidelines and blood glucose levels. It's available on iTunes for iPhone, iPad and iPod Touch.

Physicians going online for health information visit professional sites most often, and they visit WebMD's Medscape—a free portal for docs—more than any other, according to a comScore/ImpactRx study. comScore found that 81% visited sites geared toward a professional health audience during the first quarter of 2010. After Medscape, the next most popular destinations were,, and

Sending reminders in text messages to adolescent diabetes patients improved adherence to insulin regimens. Nationwide Children's Hospital in Columbus, Ohio sent “friendly, supportive” messages to a small group of teenaged patients and saw a three-fold decrease in missed doses. Non-adherence among adolescents is a big problem, running four times higher than for adults. The endocrinologist behind the study, Jennifer Dyer, MD, has developed an iPhone app to allow docs to send reminder texts to multiple patients at a time.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?